Heather Hensley, DO
Dermatology · Tempe, AZNPI 1124280953
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (43.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Dermavant Sciences, Inc. at 29.8% of the total. Reporting peaked in 2023 at $31,402 and has fallen 61.2% since, to $12,199 in 2025. Among dermatology clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 949 payments — averaging $78.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dermavant Sciences, Inc.$22K
- LEO Pharma Inc.$21K
- Galderma Laboratories, L.p.$15K
- Johnson & Johnson$3K
- AbbVie$2K
- Arcutis Biotherapeutics, Inc.$2K
- plus $10K from 27 others
What the payments were for
- Consulting fees$20,73228%
- Speaking & faculty fees$32,42044%
- Travel & lodging$1,4232%
- Food & beverage$19,30226%
- Education$1570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dermavant Sciences, Inc. | 63 | $22,099 |
| LEO Pharma Inc. | 114 | $20,802 |
| Galderma Laboratories, L.p. | 91 | $15,165 |
| Johnson & Johnson | 47 | $2,778 |
| AbbVie | 100 | $1,924 |
| Arcutis Biotherapeutics, Inc. | 26 | $1,748 |
| Sanofi | 31 | $1,221 |
| E.r. Squibb & Sons, L.L.C. | 34 | $828 |
| Amgen | 39 | $790 |
| Pfizer | 46 | $766 |
| Regeneron Healthcare Solutions, Inc. | 31 | $758 |
| Incyte Corporation | 86 | $705 |
| VYNE Pharmaceuticals Inc. | 43 | $699 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 24 | $429 |
| Novartis | 8 | $342 |
| EPI Health, LLC | 14 | $326 |
| Mayne Pharma Commercial LLC | 32 | $320 |
| Almirall LLC | 16 | $290 |
| Sun Pharmaceutical Industries Inc. | 16 | $290 |
| Journey Medical Corporation | 21 | $246 |
| Botanix SB Inc | 8 | $238 |
| Organon | 13 | $201 |
| Biofrontera Inc. | 15 | $192 |
| UCB, Inc. | 9 | $162 |
| Lilly USA, LLC | 7 | $139 |
| Revance Therapeutics, Inc. | 2 | $131 |
| Sanofi-aventis U.S. LLC | 2 | $129 |
| Janssen Scientific Affairs, LLC | 1 | $116 |
| Dermira, Inc. | 3 | $58 |
| Bristol Myers Squibb | 2 | $42 |
| Encore Dermatology Inc. | 2 | $36 |
| Boston Scientific | 1 | $35 |
| Strata Skin Sciences, Inc. | 2 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$74,034 in reported general payments places this provider in the 90th percentile of 305 dermatology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdbryTralokinumab-Ldrm | 20 | $75,065 |
| Dupixent PenDupilumab | 12 | $48,984 |
| Azelaic Acid | 11 | $1,531 |
| Ketoconazole | 95 | $1,430 |
| Fluocinonide | 31 | $1,165 |
| Fluorouracil | 16 | $1,114 |
| Ciclopirox | 24 | $778 |
| Mupirocin | 99 | $592 |
| Triamcinolone Acetonide | 83 | $536 |
| Gentamicin Sulfate | 11 | $398 |
| Doxycycline Hyclate | 32 | $397 |
| CiclopiroxCiclopirox Olamine | 16 | $253 |
| ValacyclovirValacyclovir Hcl | 13 | $196 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| LEO Pharma Inc.Adbry | $20,802 | $75,06520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 305 dermatology providers in Arizona.
Other dermatology in Tempe
- Lindsay AckermanPhoenix$1.6M
- Kathleen ObrienTucson$742K
- Nathalie ZeitouniPhoenix$584K
- John KastelerGilbert$456K
- Anthony NuaraScottsdale$432K
- Carsten HamannPhoenix$364K
- James SlighTucson$238K
- Aaron MangoldScottsdale$171K
- Susan van DykeParadise Valley$164K
- Sheila FarhangOro Valley$153K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.